Ask AI
Targeting DLL3 for EP NECs
Emerging DLL3-Targeted Therapies for Extrapulmonary Neuroendocrine Carcinomas

Released: August 15, 2025

Activity

Progress
1
Course Completed

In this episode, Dr. Daniel Morgensztern and Dr. Jonathan Strosberg discuss the emerging role of DLL3-targeted agents in the management of extrapulmonary neuroendocrine carcinomas, including:

  • The clinical implications of using DLL3 as a therapeutic target
  • The impact of emerging DLL3-targeted therapies on evolving treatment paradigms
  • How to incorporate DLL3-based treatments into clinical practice